EBOS Group CEO Adam Hall Reports Initial Holding of 13,274 Shares from Sign-On Award

Adam Hall’s CEO Appointment and Regulatory Disclosure Requirements

The initial disclosure confirms Adam Hall’s role as Chief Executive Officer of EBOS Group Limited, with his appointment to the listed entity effective from 1 July 2025. Under New Zealand’s Financial Markets Conduct Act 2013, directors and senior executives of NZX-listed companies must disclose their relevant interests in the issuer’s quoted financial products upon assuming their positions. This requirement promotes transparency regarding equity holdings of key corporate leaders.

Filed on 2 July 2026, the disclosure was submitted to NZX Limited by Janelle Cain, General Counsel of EBOS Group Limited, who certified the accuracy of the information. Such initial disclosures are standard regulatory procedures under New Zealand securities law and do not inherently signal changes in business strategy or corporate direction.

Details of the 13,274 Ordinary Shares Granted as a Sign-On Award

The company update specifies that Adam Hall’s relevant interest comprises 13,274 ordinary shares in EBOS Group Limited. These shares are ordinary quoted financial products, with Hall recorded as the registered holder. The shares were issued pursuant to a sign-on award linked to his CEO appointment, rather than acquired on-market.

Sign-on awards, also known as commencement awards, are commonly employed by large listed companies to attract senior executives, often compensating for forfeited equity at previous employers. The disclosure does not provide details on vesting conditions, holding periods, performance hurdles, or the monetary value of the award.

Regulatory Framework Under the Financial Markets Conduct Act 2013

The disclosure complies with Sections 297(1) and 298(1) of New Zealand’s Financial Markets Conduct Act 2013 (FMCA). Section 297(1) mandates initial disclosure of relevant interests by directors and senior managers upon appointment, while Section 298(1) requires ongoing notification of changes to those interests. These provisions underpin New Zealand’s regime for transparency in director and senior manager holdings, fostering investor confidence.

EBOS Group Limited’s dual listing on the ASX and NZX subjects it to regulations from both exchanges. This disclosure was made to NZX Limited under New Zealand law, reflecting the company’s incorporation and primary regulatory jurisdiction. ASX investors should note that some governance notices originate under New Zealand rules and are lodged with NZX.

No Derivative or Related Body Corporate Interests Reported

The notice confirms Adam Hall holds no derivative interests in EBOS Group financial products. All derivative-related fields such as type, underlying class, notional value, settlement, maturity, expiry, and pricing are marked not applicable. Thus, Hall’s entire disclosed interest consists solely of the 13,274 ordinary shares.

Additionally, there is no related body corporate through which Hall holds relevant interests; the shares are directly registered in his name. This straightforward ownership structure ensures a transparent disclosure profile. Any future acquisitions, disposals, or derivative positions would necessitate further disclosure under the FMCA.

General Counsel Janelle Cain’s Role in Authorising the Disclosure

The certification section notes that Janelle Cain, General Counsel of EBOS Group Limited, signed the disclosure on behalf of Adam Hall on 2 July 2026 as the authorised person. It is standard practice for general counsel or company secretaries to lodge such disclosures for senior executives in large listed companies, reflecting established governance and compliance protocols.

Cain’s involvement highlights EBOS Group’s robust governance framework managing compliance across both Australian and New Zealand regulatory environments. For a company of EBOS Group’s size and scope, timely and accurate disclosure is essential to meet obligations to shareholders and market participants on both exchanges.

About EBOS Group and the Significance of CEO Equity Disclosures

EBOS Group Limited ranks among Australasia’s largest diversified distributors of healthcare and animal care products. Its operations include pharmaceutical wholesaling, pharmacy services, medical devices, contract logistics, and consumer products across Australia, New Zealand, and Southeast Asia, making it a key player in the regional healthcare supply chain. The CEO’s appointment and equity alignment are closely watched by institutional and retail investors.

CEO equity disclosures offer investors insight into executive alignment with shareholder interests. Shares granted as part of a sign-on package typically aim to align the CEO’s financial interests with those of long-term shareholders from the outset. Investors often monitor subsequent on-market share acquisitions and the broader remuneration framework, including long-term incentives and performance conditions disclosed in annual and remuneration reports.

Market Position of EBOS Group as a Dual-Listed Healthcare Leader

EBOS Group’s dual listing on ASX and NZX reflects its significant presence in both Australian and New Zealand markets. The company has pursued organic growth and strategic acquisitions to expand its healthcare and animal care portfolio. The appointment of Adam Hall as CEO represents a material event, with investors keen to observe his strategic priorities and operational focus.

The immediate share price impact of this disclosure was not evident, as such initial director interest filings are typically viewed as compliance formalities rather than market-moving events. Nonetheless, Hall’s tenure commencement and initial equity position mark the start of a phase where market participants will evaluate leadership continuity, strategic communication, and financial performance under his guidance.

Context of Sign-On Awards in Executive Remuneration

Sign-on equity awards have become common in senior executive remuneration packages in Australia and New Zealand. They compensate incoming executives for lost entitlements at previous employers, align interests with shareholders, and signal board confidence in the executive’s long-term contribution.

Hall’s 13,274 shares, granted via sign-on award rather than market purchase, form part of his employment terms. The disclosure does not specify the award’s monetary value, any attached conditions, or whether the shares are subject to escrow or disposal restrictions. Shareholders seeking comprehensive details on Hall’s remuneration, including long-term incentives and performance rights, should consult EBOS Group’s Annual Report and remuneration disclosures.

Future Disclosure Obligations and Investor Focus on Strategic Direction

Following this initial filing, Adam Hall must comply with ongoing disclosure requirements under the Financial Markets Conduct Act 2013, notifying NZX Limited of any changes to his relevant interests in EBOS Group’s quoted financial products. This includes on-market share transactions and grants of new equity instruments such as performance rights or options. Each event triggers further disclosure, maintaining a transparent record of Hall’s evolving equity stake.

Beyond regulatory compliance, investors will closely watch Hall’s articulation of EBOS Group’s strategic vision, including acquisition plans, capital allocation, and management of its diverse healthcare and animal care businesses. Upcoming investor presentations, earnings guidance, and strategic announcements under Hall’s leadership will provide critical insights into his priorities for one of Australasia’s foremost healthcare companies.